Drugs / Pegylated Interferon-alpha

Trials 3 · a red edge is where a trial was stopped

200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2/31 trial
Phase 2/3 NCT00196638 May 2002 → Mar 2006 HIV infectious disease French National Agency for Research on AIDS and Viral Hepatitis Terminated No outcome recorded
Phase not applicable2 trials
NCT06923280 May 2025 → Dec 2027 expected chronic hepatitis B virus infection Huashan Hospital Not yet recruiting No outcome recorded
NCT00687999 Dec 2005 → Jun 2008 chronic hepatitis C virus infection Kaohsiung Medical University Chung-Ho Memorial Hospital Completed No outcome recorded
Also used as a comparator or background therapy in 3 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT00277758 Background Mar 2004 → Jul 2006 hepatitis C virus infection Weill Medical College of Cornell University Terminated No outcome recorded
Phase 21 trial
Phase 2 NCT00984620 Background Sep 2009 → Apr 2011 hepatitis C virus infection Boehringer Ingelheim Completed No outcome recorded
Phase 31 trial
Phase 3 NCT01358864 Background Jun 2011 → Feb 2013 chronic hepatitis C virus infection Boehringer Ingelheim Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as Pegylated interferon-alpha “Ribavirin + Pegylated interferon-alphaNCT00277758
6

NCT00277758

NCT01358864

NCT00687999

NCT00196638

NCT06923280

NCT00984620

Known as IFN “Pegylated Interferon-alpha (IFN)” NCT00984620
1

“Pegylated Interferon-alpha (IFN)” NCT01358864

Known as PEG-IFN-alpha PEG-IFN-alphaNCT00687999
Modality Protein / enzyme biologic “a cytokine, interferon alpha” NCT00196638
Route Subcutaneous “Pegylated-Interferon-alpha 1.5 ug/kg weekly subcutaneously.” NCT00277758